Search results for: 'glass year'

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping diagnostics, therapeutics, and clinical workflows across infectious diseases, women’s health, metabolic disorders, neurodegeneration, oncology, rare diseases, and musculoskeletal care. It hi...

In this analysis, Frost & Sullivan identifies and defines the leading trends shaping the global pharmaceutical landscape. The study period is 2022–2030, with 2024 as the base year and 2025–2028 as the forecast period. The geographic scope includes 5 regions: North America, Latin America (LATAM) and the Caribbean, Asia-Pacific (APAC), Europe, and th...

15 May 2025  |  Global  |  Market Research

Immunomodulator Therapeutics Market, Global, 2024–2030

Mechanism-targeted Approaches are Driving Transformational Growth by Enabling Innovation in Autoimmune, Oncology, and Inflammatory Therapies

Infographics

×

This research service offers a comprehensive analysis of the global immunomodulator therapeutics market, specifically targeting inflammatory disorders in the immunology, gastrointestinal (GI), and dermatology segments. The report defines this market through products designed to modify and regulate pathological immune responses, either by inhibiting...

The biopharma industry has been evolving over the past few decades. This study analyses the top ten trends that will impact the future of the biopharma industry through 2040.The future of biopharma will be driven by innovation in AI and ML, particularly generative AI, and by advancements in translational medicine and synthetic biology. Future clini...

16 Aug 2016  |  North America  |  Market Research

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Emerging Business Models Drive Transformation

Infographics

×

The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients (APIs) and intermediates; and finished dose formulations (FDFs), further segmented by solid, liquid and semi-solid, and injectable doses—and to understand the value chain from clinical to comme...

Rare diseases pose a global burden to healthcare despite making up a very small fraction of the global disease landscape. Most treatment options for rare diseases focus on maintaining the disease symptoms, rather than a disease-modifying approach. To address this unmet need, RNA therapies are emerging as disease-modifying approaches addressing the ...

Over the last 3-5 years, growing cost pressure on healthcare and pharmaceutical companies and a significant shift towards outcome based healthcare approach have resulted in companies increasingly adopting real world data and evidence solutions to optimize their operation and cost using analytics. Earlier, applications of RWE were largely limited to...

19 Sep 2018  |  North America  |  Market Research

Global Biologics Contract Development and Manufacturing Organization (CDMO) Market, Forecast to 2022

Investments in Single Use/Disposable Technologies to Capitalize on Growth Opportunities in High-value Low-volume Biologics

Infographics

×

Key Issues Addressed

The global pharmaceutical industry is evolving with the rising need for novel therapies in the changing disease landscape. As a result of rising prevalence of chronic infectious diseases as well as growing cancer incidence, market needs are shifting from traditional small molecules to large molecules. This study presents an overview of the global b...

20 Nov 2017  |  North America  |  Market Research

Global Biologics Market—Companies-to-Action

Biopharma Companies are Increasingly Collaborating with CDMOs, CROs, and Digital and Medical Equipment Companies for Biologics Discovery and Development

Infographics

×

This study on the "Global Biologics Market: Companies-to-Action" presents an overview of the global biologics landscape with an emphasis on the top 10 leading bio-pharma companies in the market. The study highlights the shifting focus and investments of bio-pharma companies towards biologics discovery and development, which is attributed to the gro...